|
|
|
|
|
| Effect of rosuvastatin on cardiac function in patients with acute ST segment elevation myocardial infarction undergoing elective PCI |
| Yang Jian-jun, Mou Hua-ming, Pang Xiao-hua, Mi Qing |
| Department of Cardi ology, Chongqing Three Gorges Central Hospital, Chongqing 404000, China |
|
|
|
|
Abstract Objective: To investigate the effect rosuvastatin on cardiac function in patients with acute ST segment elevation myocardial infarction undergoing elective percutaneous coronary intervention (PCI).Methods: 150 patients with acute STEMI treated in our hospital were divided into observation group and control group, and 75 cases in each group. The two groups were given anticoagulation, inhibition of ventricular remodeling and anti-myocardial ischemia and other conventional treatment. The patients in observation group were orally administrated with rosuvastatin 10 mg/d based on the conventional treatment 7 days before PCI. Amino acid N-terminal brain natriuretic peptide (NT-proBNP), high sensitive C reactive protein (hs-CRP) levels, 6 minutes walk distance (6MWT), ultrasound heartbeat graph data and major adverse cardiovascular events (MACE) incidence of two groups were compared at preoperative and postoperative 12 weeks. Results: At 12 weeks of post-operation, 6MWT and normal cardiac diastolic function proportion compared to pre-operation significant increase; 6MWT, normal diastolic function ratio, left ventricular ejection fraction of observation group was significantly higher than that of the control group; the NT-ProBNP, hs-CRP and MACE incidence of the observation group was significantly lower than that of the control group. The difference was statistically significant (P＜0.05). Conclusion: Patients with acute STEMI undergoing PCI oral rosuvastatin at 7 days of pre-operation can significantly reduce the inflammatory markers, significantly improve cardiac systolic and diastolic function and does not increase the incidence of major cardiovascular events, worthy of clinical reference.
|
|
Received: 26 May 2017
|
|
Corresponding Authors:
Mou Hua-ming, E-mail: abc012348@sina.com
|
|
|
|
| ［1］中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014［J］.中华心血管病杂志, 2014, 42(2):98-122.
［2］国强华,宋维鹏,贾红丹,等.左西孟旦在急性心肌梗死后心力衰竭的老年患者治疗中的临床研究［J］.实用老年医学,30(6):493-495.
［3］吕吉元.2D-STI评价冠心病患者PCI治疗前后左心功能［D］.山西医科大学第一临床医学院学报, 2014.
［4］Nagueh SF,Appleton CP,Gillebert TC,et al.Recommendations for the evaluation of left ventricular diastolic function by echocardiography［J］.J Am Soc Echocardiogr, 2009, 22(2):107-133.
［5］中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南［J］.中华心血管病杂志, 2010, 38(8):675-690.
［6］Cohen M, Boiangiu C, Abidi M.Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy［J］.J Am Coll Cardiol, 2010, 55(18):1895-1906.
［7］李军.影响急性 ST 段抬高型心肌梗死患者入院时心功能的危险因素分析［J］.心脏杂志, 2015, 27(6):683-686.
［8］蔡立慧,李庐,魏少君.6分钟步行试验在心血管患者心功能康复评价中的运用［J］.中国现代药物应用, 2016,10(13):280-281.
［9］中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南［J］.中华心血管病杂志, 2015, 43(5):380-393.
［10］李翔,高毅滨,郑文武.瑞舒伐他汀治疗早发冠心病急性心肌梗死临床观察［J］.山东医药, 2015, 55(25):44-45.
［11］Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L,et al.Tumour necrosis factor alpha and troponin T as a predictor of poor prognosis in patients with stableheart failure［J］.Clin Invest Med, 2005, 28(1):23-29.
［12］Yin WH, Chen JW,Jen HL,et al.Independent prognostic value of elevated high- sensitivity C- reactive protein in chronic heart failure［J］. Am Heart J, 2004, 147(5):931-938.
［13］梁文霞.瑞舒伐他汀对血脂正常的 2型糖尿病患者血清高敏 C 反应蛋白的作用［J］.中国心血管病研究, 2014, 12(7):644-646.
［14］严庆场,吴广华.瑞舒伐他汀对急性冠脉综合征患者 CRP,LOX-1的影响［J］ . 中华全科医学, 2011, 9(4) :581，632.
［15］Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein［J］. J Nephrol, 2009, 22(1):83-89.
［16］Verma A, Ranganna KM, Reddy RS, et al.Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease［J］. Am J Cardiol, 2005, 96(9):1290-1292. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
